Early Access — free while we kick the tires
EdgarHawk

Sturge Simon

Director

Director
1 filing analyzed · 1 company · Latest 2024-10-08

Companies

Company Buys Sells Direction
MoonLake Immunotherapeutics MLTX 0 1 Net selling

Activity

October 2024
high
Sell
171,000 shares
$9,186,120
Significance 7/10

Director Sturge Simon sold 171,000 shares of MLTX at $53.72 ($9.2M) on 2024-10-04, reducing holdings by 49.9% while company unprofitable at -$24.3M net income.

Sturge Simon executed a substantial sale of 171,000 shares—exactly half his pre-transaction position of 342,980 shares—at $53.72, raising $9,186,120.00. This divestiture is material in size and represents a significant reduction in his equity stake in MLTX. The timing coincides with stock trading near its 52-week high ($63.86), though 21.9% below peak; the company remains unprofitable with full-year net income of -$24,267,012.00 against a market cap of $2,627,150,383.35. The magnitude and precision of the 50% stake reduction warrants investor attention to whether this reflects fundamental concerns about the company's path to profitability or portfolio rebalancing unrelated to operational outlook.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access